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SUMMARY The treatment of 450 consecutive new
patients with pulmonaryTB was evaluated to determine
outcome following directly-observed treatment. In all,176
(39.1%) patients were cured, 23 (5.1%) completed treat-
ment, 80 (17.8%) defaulted treatment, 24 (5.3%) died, 54
(12.0%) were lost to follow-up and 93 (20.7%) were trans-
ferred out. Increasing agewas significant for death. Males
were more likely to default and those with negative pre-
treatment sputum smears and those whowere unem-
ployedweremore likely to be lost to follow-up.The overall
treatment success rate remains low.Ourdata suggests that
greateremphasis is needed to improveTB treatment success.
Introduction
Globally South Africa ranks seventh in terms of the TB
burden.1 In response to the growing TB burden, the South
African National TB Control Programme (NTP) estab-
lished standardized guidelines for TB case management,
enhanced accessibility to services and adherence to treat-
ment through the directly-observed therapy short-course
(DOTS) strategy.2,3 Despite these advances, there are wide
regional variations in TB cure rates. The aim of this study
was to evaluate pulmonary TB (PTB) treatment outcome
following directly-observed treatment (DOT) and to identify
risk factors for these outcomes.
Materials andmethods
This study was conducted at the Prince Cyril Zulu
Communicable Diseases Centre located in metropolitan
Durban, KwaZulu-Natal, South Africa. The clinic is an
outpatient specialist TB facility serving mainly the local
indigent public sector users of health services. TB
diagnosis and management at the clinic is in accordance
with the NTP3 and World Health Organization (WHO)4
guidelines. Four hundred and fifty patients diagnosed and
registered for PTB treatment between April and June 2001
were prospectively followed to final outcome. Patient’s
demographics, clinical history, sputum smear microscopy
and reported chest X-ray results, TB treatment, treatment
provider and treatment outcomes were assessed. Treat-
ment outcomes1,3,4 were categorized as cured, completed
treatment, defaulted treatment, transferred out, treatment
failure and lost to follow-up.5 Data were analysed using
SAS Software (SAS Institute, Inc. Carey NC). w2 and
Fisher’s exact tests were used to compare risk factors. The
multinomial regression model was built, testing gender,
age, direct sputum smear result and employment status
with each outcome using cured as the comparison group.
Relative risk was used to report the strength of the
association. P values of less than 0.05 were considered
statistically significant.
Results
The median age was 32 (interquartile range [IQR]: 25–40)
years. The majority of the patients were men. Women
were significantly younger (median age of 29.0 [IQR:
24–38] years) compared to men (median age of 33.0 [IQR:
26–41] years); (Po0.001). More than half (254; 56.4%)
were unemployed. A previous episode of TB was reported
in 24 (5.3%) patients and four (0.5%) patients reported
more than one episode of TB. About one in five reported a
family history of TB. The sputum smears at the first visit
were positive in 292 (64.8%) with 14 (3.1%) positive at
2 months and all of those tested, negative at 6 months. In
419 (92.9%) patients, the chest X-rays were reported as
active TB, with 201 (44.6%) and 108 (24.0%) showing
improvement by the 2- and 6-month visit, respectively.
In all, 176 (39.1%) patients were cured, 23 (5.1%)
completed treatment, 80 (17.8%) defaulted, 24 (5.3%)
died, 54 (12.0%) were lost to follow-up and 93 (20.7%)
were transferred out. The overall treatment success rate
for the cohort was 44.2% while for sputum smear positive
TB patients it was 44.8% (Table 1). In the multinomial
regression analysis, increasing age (relative risk [RR] 1.3;
95% confidence interval [CI] 1.0–1.5; P¼ 0.004) remained
significant for death. Males were more likely to default
(25.6% versus 16.9%; RR 1.9; 95% CI 1.0–3.5; P¼ 0.05).
The risk for loss to follow-up was higher in those with
negative pretreatment direct sputum smears (25.7%
versus 12.4%; RR 2.2; 95% CI 1.0–4.8; P¼ 0.04) and in
the unemployed (19.5% versus 9.5%; RR 2.6; 95% CI
1.2–5.3; P¼ 0.008) (Table 2).
Discussion
Whilst the NTP2,3 has enhanced its efforts towards the
early detection and management of TB, the cure rate
(39.1%) remains low and the default rate (17.8%) remains
high. For any meaningful change to occur within the
burden of TB, WHO recommends the cure rate for
sputum positive cases to be greater than 85% and the
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default rate to be less than 10%. A high proportion (12%)
of patients were lost to follow-up and not identified
through the WHO treatment outcome criterion.1,4 Males
and the unemployed were more likely to be lost to follow-
up suggesting that this group may represent a mobile
population contributing to the high burden of TB often
exacerbated within communities affected by poverty, poor
socio-economic conditions and HIV infection.6 While the
mortality rate of 5% is perhaps a conservative estimate,
defaulting and lost to follow-up patients may have
contributed to the mortality. Deaths could have occurred
during the early stages of diagnosis, hence the inability to
trace patients and record these deaths accurately. In
resource-poor countries, deaths from TB in pre-HIV era
were relatively low,7 however, the escalating burden of
HIV and HIV-related TB as a complication of AIDS, has
a major impact on TB transmission,6 treatment outcome8
and mortality rate.8 Furthermore, our patients who died
were all much younger, compared with patients from
developed communities who have TB and die with
advancing age. For the 20% of patients transferring out
to other reporting units, we were unable to obtain
information about their treatment outcome. This empha-
sizes the need to enhance our efforts to retain patients
until completion of treatment or for a systematic referral
and recording system to track such patients.
In this study, sputum smear microscopy was positive in
64.8% of patients and remains the mainstay for the
diagnosis of PTB in resource-poor settings. The perfor-
mance and sensitivity of sputum smear microscopy is
known to decline and may have been compromised with
advancing HIV disease9 often presenting diagnostic
challenges. Our data strengthens the case for the need to
undertake additional research on on-site diagnosis to
differentiate the reasons for the reduced sensitivity such as
the low numbers of detectable bacilli in sputum specimens
with advancing HIV disease. Despite the declining
sensitivity of sputum smear microscopy, it remains an
important tool for diagnosing the majority of cases.
This study has both strengths and limitations. The use of
routinely-collected data10 demonstrates the realities of a
routine TB programme, whilst the quality of the data may be
a limitation. Furthermore voluntary counselling and testing
services for HIV are not routinely offered and explains the
absence of any reliable estimates of TB and HIV co-infection.
Conclusion
Overall, our results demonstrate the poor treatment
outcomes. Early diagnosis, reliable reporting systems for
transfer-outs, procedures to prevent defaulting and more
importantly those lost to follow-up need to be enhanced.
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Table1 TB treatment outcomes
Treatment outcome
Outcome
Sputum smear positive (n=292) Overall (n=450)
n % (95% CI) n % (95%CI)
Cured 128 43.8 (38.1--49.7) 176 39.1 (34.5--43.7)
Treatment completed 3 1.0 (0.2--2.9) 23 5.1 (3.2--7.6)
Treatment interruption -- defaulter 53 18.2 (13.9--23.0) 80 17.8 (14.3--21.6)
Died 14 4.8 (2.6--7.9) 24 5.3 (3.4--7.8)
Lost to follow-up 32 10.9 (7.6--15.1) 54 12.0 (9.1--15.4)
Transferred out 62 21.3 (16.6--26.4) 93 20.7 (17.0--24.7)
CI, confidence interval
Table 2 Risk factors associatedwithTB treatment outcomes
Unadjusted Adjusted*
Risk Factors Outcomew RR 95% CI RR 95% CI P-value
Age (per 5 years) Died 1.3 1.1--1.5 1.3 1.1--1.5 0.004
Lost to follow-up 0.9 0.8--1.0 0.9 0.9--1.0 0.07
Defaulters 0.9 0.8--1.0 0.9 0.95--1.0 0.2
Gender (male) Died 1.2 0.5--3.1 1.1 0.4--3.0 0.8
Lost to follow-up 0.9 0.5--1.6 1.2 0.6--2.3 0.6
Defaulters 1.7 0.9--2.9 1.9 1.0--3.5 0.05
Direct Sputum smear (negative) Died 1.5 0.5--4.5 1.1 0.3--3.6 0.1
Lost to follow-up 2.6 1.3--5.2 2.2 1.0--4.8 0.04
Defaulters 1.0 0.5--2.2 1.0 0.5--2.3 0.9
Employment status (unemployed) Died 1.4 0.6--3.6 1.6 0.6--4.4 0.2
Lost to follow-up 2.7 1.3--5.3 2.6 1.2--5.3 0.008
Defaulters 1.6 0.9--2.8 1.5 0.8--2.6 0.1
Adjusted for risk factors listed; wOutcome: cured (includes treatment completed)
RR, relative risk; CI, confidence interval
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SUMMARY In this study, we evaluated the usage of the
Pan Malaria IgG CELISA test in the diagnosis of malarial
infections in Siverek-Sanliurfa,Turkey, wheremalarial
infection is endemic and there areminimal health services
available.The Pan Malaria IgG CELISA (Cellabs) test, which
uses recombinant antigens and detects exposure to all
four forms of malaria (P. falciparum, P. vivax, P. ovale
and P. malariae) was used as individuals. Using the con-
sensus microscopy results as the standard, sensitivity of
ELISA for detection of any malarial infection in the rural
populations was 83%, specificity was 85%.These results
show that the performance of ELISA for the detection of
any malarial infection is adequate for acute- and post-
emergency situations and rural populations when the
alternative is just clinical diagnosis.
Introduction
Malarial infection remains a devastating global problem,
with an estimated 300–500 million cases occurring
annually. Forty-one percent of the World’s population
live in areas where malaria is transmitted (e.g., parts of
Africa, Asia, the Middle East, Central and South
America, Hispaniola, and Oceania), and 700,000—2.7
million people die of malaria each year.1,2 Malaria has the
potential to be one of the important diseases in this
century in Turkey.3 There are four species causing human
malaria: Plasmodium falciparum, Plasmodium vivax,
Plasmodium ovale and Plasmodium malaria.4
In patients with malaria, a prompt and accurate
diagnosis is the key to effective disease management.
The gold standard test for Plasmodium spp. diagnosis is
microscope examination of Giemsa-stained thick and thin
blood smears. Although this method is a rapid and
inexpensive diagnostic test, it depends on the micro-
scopist’s experience; achieving high sensitivity requires
counting up to 100 microscope fields which is time-
consuming and labour-intensive.5 However, serological
tests have recently been established as alternative methods
to conventional microscopy for the diagnosis of malar-
ia.6–10 ELISA kits can detect antigen and antibody
reliably and can be quite specific for malaria. To
determine the diagnostic value of the Pan Malaria IgG
CELISA test in this study, assay with P. vivax malaria
patients according to clinical findings and the results of
direct microscopy were utilized.
Methods
This study was undertaken in rural villages of Sanliurfa,
Turkey, which is an area endemic for malaria during the
period April–August 2003. Thick and thin blood films were
collected from 759 people who had malaria-like symptoms
such as fever and chills. Air-dried thick and thin blood
films were stained with Giemsa. Stained slides were then
examined under a compound light microscope using 1000x
oil immersion magnification. Slides were reexamined by a
second microscopist at a reference laboratory.
The Pan Malaria IgG CELISA (Cellabs Pty Ltd,
Brookvale NSW, Australia) kits that we used in our
study makes it possible to determinate four Plasmodium
species (P. vivax, P. falciparum, P. ovale, P. malariae).
Sera samples were kept at 801C.
Data was collected and analysed using the SPSS
(SPSS, Chicago, USA) statistical programme. For sensi-
tivity and specificity, the test kits were compared with the
microscopic results of Giemsa-stained smears. Sensitivity
was calculated as the proportion of positive test results
obtained among samples containing malarial parasites by
microscopy; specificity was calculated as the proportion of
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